CLOs on the Move

Infinity Pharmaceuticals Inc

www.ipi.com

 
Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ipi.com
  • 780 Memorial Dr
    Cambridge, MA USA '02139
  • Phone: 617.453.1000

Executives

Name Title Contact Details

Similar Companies

Medsource RX

Medsource RX is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Huyabio

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

National Diabetic Pharmacies

National Diabetic Pharmacies is a Salem, VA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Beckman Coulter

Beckman Coulter Inc. is a Danaher Corporation company that develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing.

Silence Therapeutics

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.